AR051770A1 - Compuestos moduladores de los receptores de tipo ppar(gamma) y su utilizacion en composiciones cosmeticas y farmaceuticas - Google Patents

Compuestos moduladores de los receptores de tipo ppar(gamma) y su utilizacion en composiciones cosmeticas y farmaceuticas

Info

Publication number
AR051770A1
AR051770A1 ARP050104852A ARP050104852A AR051770A1 AR 051770 A1 AR051770 A1 AR 051770A1 AR P050104852 A ARP050104852 A AR P050104852A AR P050104852 A ARP050104852 A AR P050104852A AR 051770 A1 AR051770 A1 AR 051770A1
Authority
AR
Argentina
Prior art keywords
radical
atom
formula
alkyl
aralkyl
Prior art date
Application number
ARP050104852A
Other languages
English (en)
Inventor
Jean-Guy Boiteau
Laurence Clary
Barbuis Corinne Millois
Original Assignee
Galderma Res & Dev
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Galderma Res & Dev filed Critical Galderma Res & Dev
Publication of AR051770A1 publication Critical patent/AR051770A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/06—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring carbon atoms
    • C07D333/24—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/54—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/55—Acids; Esters
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/75—Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/26—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/42—One nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D307/38—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D307/54—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals

Abstract

Compuestos moduladores de los receptores de tipo PPARg, su método de preparacion, y su utilizacion en composiciones farmacéuticas destinadas a un uso en medicina humana o veterinaria 8en dermatología, así como en el ámbito de las enfermedades cardiovasculares, de las enfermedades inmunitarias y/o de las enfermedades relacionadas con el metabolismo de los lípidos), o incluso en composiciones cosméticas. Reivindicacion 1: Compuestos caracterizados porque responden a la formula (1) en la cual R1 representa un radical de formula (2) o (3); R5 tiene las significaciones que se dan más adelante; R2 representa un radical de formula (CH2)m-NR6-CQ-(NH)nR7; Q, R6, R7, m, n, tienen las significaciones dadas más adelante; R3 y R4, idénticos o diferentes, representan un átomo de H, un átomo de halogeno, un radical alquilo C1-12 que puede ser interrumpido por átomos de O, de F o de N, linear o cíclico, un radical hidroxilo, un radical alcoxi C1-10, un radical poliéter, un radical aralquilo, un radical ariloxi; R5 representa un radical hidroxilo, un radical OR8 o un radical hidroxilamina; R8 es tal como se define más adelante; R6 representa un radical alquilo inferior C1-4; R7 representa un radical alquilo C1-12, un radical rilo, un radical aralquilo, un radical heteroarilo, un radical heterocíclico; R8 representa un radical alquilo, arilo o aralquilo, m, n pueden tomar los valores 0 o 1; Q representa un átomo de O o de S; Ar1 y Ar2 pueden ser idénticos o diferentes, y representan un radical aromático substituido, eventualmente, de las formulas (4); A representa un átomo de S, de O o un radical N-R9; R9 representa un átomo de h o un radical alquilo C1-12; y se entiende que cuando Ar1 o Ar2 es un radical arilo, entonces, Ar2 o Ar1 es, obligatoriamente, un radical heteroarilo, y los isomeros opticos y geométricos de dichos compuestos de formula (1).
ARP050104852A 2004-11-19 2005-11-18 Compuestos moduladores de los receptores de tipo ppar(gamma) y su utilizacion en composiciones cosmeticas y farmaceuticas AR051770A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR0412326A FR2878247B1 (fr) 2004-11-19 2004-11-19 Nouveaux composes modulateurs des recepteurs de type ppary et leur utilisation dans des compositions cosmetiques ou pharmaceutiques

Publications (1)

Publication Number Publication Date
AR051770A1 true AR051770A1 (es) 2007-02-07

Family

ID=34952853

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP050104852A AR051770A1 (es) 2004-11-19 2005-11-18 Compuestos moduladores de los receptores de tipo ppar(gamma) y su utilizacion en composiciones cosmeticas y farmaceuticas

Country Status (8)

Country Link
US (3) US8129416B2 (es)
CN (1) CN101103012A (es)
AR (1) AR051770A1 (es)
AT (1) ATE500239T1 (es)
BR (1) BRPI0516811A (es)
DE (1) DE602005026689D1 (es)
FR (1) FR2878247B1 (es)
RU (1) RU2007122767A (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20070047308A (ko) * 2004-08-17 2007-05-04 갈데르마 리써어치 앤드 디벨로프먼트 Ｐｐａｒ 유형 수용체를 활성화시키는 신규 이방향족화합물, 및 미용 또는 약학적 조성물에서의 그의 용도
FR2892412B1 (fr) * 2005-10-26 2008-05-16 Galderma Res & Dev Composes biaromatiques modulateurs des ppars
NZ584454A (en) 2007-10-12 2011-09-30 Ingenium Pharmaceuticals Gmbh N-[6-phenyl-pyrimidin-4-yl]-amides and urea derivatives as inhibitors of protein kinases
CN102834380B (zh) 2010-03-10 2015-04-01 阿斯利康公司 蛋白激酶的抑制剂
US8653269B2 (en) 2010-03-12 2014-02-18 Nippon Soda Co., Ltd. Process for preparation of t-butoxycarbonylamine compounds
CN107531660A (zh) 2015-03-13 2018-01-02 福马治疗股份有限公司 作为HDAC8抑制剂的α‑肉桂酰胺化合物和组合物

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2812876B1 (fr) 2000-08-08 2002-09-27 Galderma Res & Dev Nouveaux composes bi-aromatiques activateurs des recepteurs de type ppar-gamma et leur utilisation dans des compositions cosmetiques ou pharmaceutiques
US6908939B2 (en) 2001-12-21 2005-06-21 Galderma Research & Development S.N.C. Biaromatic ligand activators of PPARγ receptors
FR2833949B1 (fr) * 2001-12-21 2005-08-05 Galderma Res & Dev NOUVEAUX LIGANDS ACTIVATEURS DES RECEPTEURS PPARy, LEUR PROCEDE DE PREPARATION ET LEUR UTILISATION EN MEDECINE HUMAINE AINSI QU'EN COSMETIQUE
WO2004024939A2 (en) * 2002-09-13 2004-03-25 Georgetown University Ligands for the peroxisome proliferator-activated receptor, and methods of use thereof
CA2505299C (en) 2002-11-19 2012-11-13 Galderma Research & Development, S.N.C. Novel biaromatic compunds which activate ppary type receptors, and use therof in cosmetic or pharmaceutical compositions
FR2847251B1 (fr) * 2002-11-19 2006-11-17 NOUVEAUX COMPOSES BI-AROMATIQUES ACTIVEURS DES RECEPTEURS DE TYPE PPARy ET LEUR UTILISATION DANS DES COMPOSITIONS COSMETIQUES OU PHARMACEUTIQUES
FR2847580B1 (fr) * 2002-11-25 2006-03-03 Galderma Res & Dev NOUVEAUX COMPOSES BI-AROMATIQUES ACTIVATEURS DES RECEPTEURS DE TYPE PPARy ET LEUR UTILISATION DANS DES COMPOSITIONS COSMETIQUES OU PHARMACEUTIQUES
EP1572629A1 (en) 2002-12-12 2005-09-14 Galderma Research & Development, S.N.C. COMPOUNDS WHICH MODULATE PPARϝ TYPE RECEPTORS, AND USE THEREOF IN COSMETIC OR PHARMACEUTICAL COMPOSITIONS
FR2848553B1 (fr) * 2002-12-12 2007-03-30 Galderma Res & Dev Nouveaux composes modulateurs des recepteurs de type ppary et leur utilisation dans des compositions cosmetiques ou pharmaceutiques
BRPI0411674A (pt) * 2003-06-20 2006-08-29 Galderma Res & Dev compostos, composição cosmética, uso cosmético de uma composição, uso de um composto, composição farmacêutica, e processo cosmético para o embelezamento da pele

Also Published As

Publication number Publication date
FR2878247A1 (fr) 2006-05-26
US20130303549A1 (en) 2013-11-14
CN101103012A (zh) 2008-01-09
US20120121527A1 (en) 2012-05-17
DE602005026689D1 (de) 2011-04-14
RU2007122767A (ru) 2008-12-27
BRPI0516811A (pt) 2008-09-23
US20080027077A1 (en) 2008-01-31
US8129416B2 (en) 2012-03-06
FR2878247B1 (fr) 2008-10-03
ATE500239T1 (de) 2011-03-15
US8513297B2 (en) 2013-08-20

Similar Documents

Publication Publication Date Title
AR051770A1 (es) Compuestos moduladores de los receptores de tipo ppar(gamma) y su utilizacion en composiciones cosmeticas y farmaceuticas
CY1123645T1 (el) Δικυκλικα παραγωγα, μεθοδος για παρασκευη αυτων και φαρμακευτικες συνθεσεις που περιεχουν αυτα
EA201891841A1 (ru) 6,7-дигидро-5h-бензо[7]аннуленовые производные в качестве модуляторов эстрогеновых рецепторов
AR058155A1 (es) Compuestos biaromaticos moduladores de ppars
AR081058A1 (es) Derivados de arilmetoxi isoindolina, composiciones que los comprenden y su uso en el tratamiento del cancer.
AR081758A1 (es) Compuestos cefem que tienen un grupo catecol, composiciones farmaceuticas que los contienen y su uso en el tratamiento de enfermedades infecciosas
AR054508A1 (es) Compuesto de bencilpiperazina, su uso para preparar un medicamento, procedimientos para la preparacion de dicho compuesto y de compuestos intermediarios, dichos compuestos intermediarios, composicion farmaceutica que lo comprende y procedimiento para prepararla
MY138906A (en) Phenyl derivatives as ppar agonists
AR110153A1 (es) ÁCIDOS PROPIÓNICOS 3-SUSTITUIDOS COMO INHIBIDORES DE LA INTEGRINA aV
AR077598A1 (es) Compuestos heterociclicos fusionados como modulares de canales ionicos
AR072906A1 (es) Nucleosidos modificados utiles como antivirales
AR078549A1 (es) Antagonistas de la via de wnt y composiciones farmaceuticas que los contienen
ECSP088829A (es) Derivados de bencimidazol 5-sulfonamida como ligandos del receptor cannabinoide 1 (cb1)
CO6341634A2 (es) Nuevos derivados de imidazo(1,2-a)pirimidina, su procesamiento de preparacion, su aplicacion como medicamentos, composiciones farmaceuticas y nueva utilizacion particularmente como inhibidores de met
AR099874A1 (es) CROMENO Y 1,1A,2,7B-TETRAHIDROCICLOPROPA[C]CROMENO PIRIDOPIRAZINADIONAS COMO MODULADORES DE g-SECRETASA
AR054678A1 (es) Compuestos bi-aromaticos activadores de los receptores del tipo ppar y su utilizacion en composiciones cosmeticas o farmaceuticas y dichas composiciones
DOP2017000188A (es) Compuestos de benzoxaborol 4-sustituidos y uso de los mismos
AR050695A1 (es) Compuestos biaromaticos activadores de los receptores de tipo ppar y su utilizacion en composiciones cosmeticas o farmaceuticas
ATE414689T1 (de) Biphenylderivate, die sich als rar-rezeptor- aktivierende liganden eignen, verfahren zu deren herstellung und deren verwendung in der humanmedizin und in kosmetika
NI201000134A (es) Nuevos derivados dihidroindolonas, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen.
AR067056A1 (es) Compuesto de espiroindolina, sal farmaceuticamente aceptable del mismo, composicion que lo comprende y su uso para preparar un medicamento
UY29739A1 (es) Derivados de amidas o sales farmacéuticamente aceptables de los mismos, procesos de preparaciones farmacéuticas conteniéndolos y aplicaciones
AR053835A1 (es) Tetrahidropiridoazepin - 8 - onas como moduladores del receptor de dopamina d2 y compuestos relacionados para el tratamiento de la esquizofrenia y otros trastornos del snc, composiciones farmaceuticas que los contienen y su empleo en la preparacion de medicamentos.
AR055113A1 (es) Piperazinas acetilenicas como antagonistas de receptores de glutamato metabotropicos
CY1116667T1 (el) Γαλακτωμα ελαιου σε νερο μομεταζονης και προπυλενογλυκολης

Legal Events

Date Code Title Description
FA Abandonment or withdrawal